X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Aurobindo Pharma with AANJANEYA LIFECARE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs DR. DATSONS LABS - Comparison Results

AUROBINDO PHARMA     Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA DR. DATSONS LABS AUROBINDO PHARMA/
DR. DATSONS LABS
 
P/E (TTM) x 14.1 -10.9 - View Chart
P/BV x 2.8 0.2 1,753.2% View Chart
Dividend Yield % 0.4 0.0 -  

Financials

 AUROBINDO PHARMA   DR. DATSONS LABS
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-18
DR. DATSONS LABS
Mar-14
AUROBINDO PHARMA/
DR. DATSONS LABS
5-Yr Chart
Click to enlarge
High Rs809126 644.1%   
Low Rs50431 1,631.1%   
Sales per share (Unadj.) Rs281.1133.0 211.3%  
Earnings per share (Unadj.) Rs41.40.2 27,277.1%  
Cash flow per share (Unadj.) Rs50.96.6 770.0%  
Dividends per share (Unadj.) Rs2.500-  
Dividend yield (eoy) %0.40-  
Book value per share (Unadj.) Rs199.4128.8 154.8%  
Shares outstanding (eoy) m585.8831.66 1,850.5%   
Bonus/Rights/Conversions -FCCB-  
Price / Sales ratio x2.30.6 397.0%   
Avg P/E ratio x15.9516.1 3.1%  
P/CF ratio (eoy) x12.911.8 109.0%  
Price / Book Value ratio x3.30.6 542.0%  
Dividend payout %6.00-   
Avg Mkt Cap Rs m384,6302,477 15,525.6%   
No. of employees `00017.3NA-   
Total wages/salary Rs m21,30856 38,050.7%   
Avg. sales/employee Rs Th9,500.7NM-  
Avg. wages/employee Rs Th1,229.4NM-  
Avg. net profit/employee Rs Th1,397.9NM-  
INCOME DATA
Net Sales Rs m164,6664,211 3,910.8%  
Other income Rs m1,02079 1,295.8%   
Total revenues Rs m165,6864,289 3,862.9%   
Gross profit Rs m37,718569 6,633.4%  
Depreciation Rs m5,580204 2,729.8%   
Interest Rs m777430 180.7%   
Profit before tax Rs m32,38013 254,963.8%   
Minority Interest Rs m310-   
Prior Period Items Rs m0-2 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m8,1836 134,142.6%   
Profit after tax Rs m24,2295 504,772.9%  
Gross profit margin %22.913.5 169.6%  
Effective tax rate %25.348.0 52.6%   
Net profit margin %14.70.1 12,907.0%  
BALANCE SHEET DATA
Current assets Rs m121,8786,852 1,778.8%   
Current liabilities Rs m86,8066,711 1,293.6%   
Net working cap to sales %21.33.3 636.0%  
Current ratio x1.41.0 137.5%  
Inventory Days Days130161 80.7%  
Debtors Days Days68318 21.5%  
Net fixed assets Rs m81,0373,673 2,206.3%   
Share capital Rs m586317 185.1%   
"Free" reserves Rs m116,2183,761 3,090.1%   
Net worth Rs m116,8044,078 2,864.6%   
Long term debt Rs m4,5121,671 270.1%   
Total assets Rs m211,05212,633 1,670.7%  
Interest coverage x42.71.0 4,144.0%   
Debt to equity ratio x00.4 9.4%  
Sales to assets ratio x0.80.3 234.1%   
Return on assets %11.83.4 344.1%  
Return on equity %20.70.1 17,621.0%  
Return on capital %27.47.7 356.5%  
Exports to sales %022.9 0.0%   
Imports to sales %014.3 0.0%   
Exports (fob) Rs mNA964 0.0%   
Imports (cif) Rs mNA602 0.0%   
Fx inflow Rs m80,727964 8,374.2%   
Fx outflow Rs m34,700607 5,715.7%   
Net fx Rs m46,027357 12,896.3%   
CASH FLOW
From Operations Rs m19,5481,345 1,453.6%  
From Investments Rs m-19,570-2,256 867.6%  
From Financial Activity Rs m8,642-1,200 -720.2%  
Net Cashflow Rs m8,922-2,111 -422.7%  

Share Holding

Indian Promoters % 54.1 4.5 1,194.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.0 0.0 -  
FIIs % 27.7 1.4 2,051.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.2 94.1 10.8%  
Shareholders   69,601 20,807 334.5%  
Pledged promoter(s) holding % 8.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   AJANTA PHARMA  GLENMARK PHARMA  SUN PHARMA  STRIDES PHARMA SCIENCE  FDC LTD.  

Compare AUROBINDO PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Jalan Committee Recommendations; US-China Trade Worries; Key Q1FY20 Results and Top Stocks in Action(Pre-Open)

On Thursday, the Indian share markets fell sharply in late trade as US-China trade worries dragged global peers.

Related Views on News

AUROBINDO PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 10.9% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 10.9% YoY). Sales on the other hand came in at Rs 53 bn (up 30.7% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 19.3% (Quarterly Result Update)

Feb 12, 2019 | Updated on Feb 12, 2019

For the quarter ended December 2018, AUROBINDO PHARMA has posted a net profit of Rs 7 bn (up 19.3% YoY). Sales on the other hand came in at Rs 53 bn (up 21.5% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 19, 2018 | Updated on Dec 19, 2018

Here's an analysis of the annual report of AUROBINDO PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of AUROBINDO PHARMA. Also includes updates on the valuation of AUROBINDO PHARMA.

AUROBINDO PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 21.6% (Quarterly Result Update)

Nov 14, 2018 | Updated on Nov 14, 2018

For the quarter ended September 2018, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (down 21.6% YoY). Sales on the other hand came in at Rs 48 bn (up 7.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (1QFY19); Net Profit Down 12.0% (Quarterly Result Update)

Aug 13, 2018 | Updated on Aug 13, 2018

For the quarter ended June 2018, AUROBINDO PHARMA has posted a net profit of Rs 5 bn (down 12.0% YoY). Sales on the other hand came in at Rs 43 bn (up 15.5% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

More Views on News

Most Popular

These 3 Smallcap Stocks are Set to Make the Most of Smallcap Rebound(Profit Hunter)

Jul 9, 2019

As the sense of normalcy returns to the markets, the rebound in the quality smallcaps could be huge.

2 Stocks from Super Investor Sanjay Bakshi's Portfolio You Can Bet On...(The 5 Minute Wrapup)

Jul 12, 2019

Despite the current fear prevailing in the markets, both these stocks have the potential to deliver in 4-5 years.

After Disappointing Budget, Here's a Document that Concerns Largecap and Smallcap Investors(The 5 Minute Wrapup)

Jul 8, 2019

A new 'definition' of the stock universe that triggered the smallcap sell-off is back with the latest list...

Here's What to Do with Falling Small Cap Stocks(Profit Hunter)

Jul 10, 2019

There are some great buying opportunities in the market right now - and the small cap space is your best bet.

Budget an Icing on the Cake for This Smart Money Backed Affordable Housing Stock(The 5 Minute Wrapup)

Jul 10, 2019

Affordable housing is one of the most straightforward growth stories in India. This will help the real estate sector to come out of the slump.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Jul 19, 2019 09:15 AM

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA 8-QTR ANALYSIS

COMPARE AUROBINDO PHARMA WITH

MARKET STATS